TransThera's Tinengotinib Receives Priority Review Status in China for Advanced Cholangiocarcinoma Treatment
核心洞察
TransThera Sciences (搜索) announced that Tinengotinib tablets have been included in the Priority Review List by China's NMPA for treating advanced cholangiocarcinoma (搜索) patients who have received prior systemic and FGFR (搜索) inhibitor treatments.
The multi-kinase inhibitor targets FGFRs/VEGFRs, Aurora kinases (搜索), and JAK (搜索) pathways, with ongoing clinical trials in the US and China demonstrating efficacy potential across various solid tumors (搜索).
Tinengotinib has previously received multiple regulatory designations including Breakthrough Therapy Designation from NMPA, Orphan Drug and Fast Track designations from FDA, and Orphan Drug designation from EMA.
TransThera Sciences (搜索) Nanjing, Inc. announced that its investigational drug Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation of China's National Medical Products Administration. The proposed indication targets adults with unresectable advanced or metastatic cholangiocarcinoma (搜索) who have received at least one prior systemic treatment and FGFR (搜索) inhibitor treatment.
The priority review designation represents a significant regulatory milestone for the company, building upon Tinengotinib's previous Breakthrough Therapy Designation granted by the NMPA for cholangiocarcinoma (搜索) treatment.
Multi-Target Mechanism and Clinical Development
Tinengotinib is an internally discovered, registrational clinical stage multi-kinase inhibitor that exerts antitumor effects by targeting multiple pathways including FGFRs/VEGFRs, Aurora kinases (搜索), and Janus kinases (JAK (搜索)). The drug candidate is currently being evaluated in ongoing clinical trials conducted in both the United States and China, which have revealed the potential for efficacy across various solid tumors (搜索).
Regulatory Recognition Across Multiple Jurisdictions
The investigational therapy has garnered substantial regulatory attention globally. In addition to the recent priority review status in China, Tinengotinib has received Orphan Drug Designation and Fast Track Designation from the FDA for cholangiocarcinoma (搜索) treatment. The European Medicines Agency has also granted Orphan Drug Designation for biliary tract cancer (搜索) treatment.
Company Focus and Strategic Positioning
TransThera describes itself as a clinical demand-oriented, registrational clinical-stage biopharmaceutical company focused on discovering and developing innovative small molecule therapies for oncology, inflammatory, and cardiometabolic diseases. The company aims to develop first-in-class or best-in-class drug candidates strategically positioned to meet urgent clinical needs on a global scale, supported by in-depth translational medicine and drug design studies.